# Molecular signatures and causal factors underlying latent cytomegalovirus infection among people living with HIV (PLHIV)

**Authors:** Nhan Nguyen, Zhenhua Zhang, Xun Jiang, Nienke van Unen, Jéssica C. dos Santos, Liang Zhou, Vasiliki Matzaraki, Javier Botey-Bataller, Marc Blaauw, Wilhelm A. J. W. Vos, Louise van Eekeren, Annelies Verbon, Albert L. Groenendijk, Janneke E. Stalenhoef, Marvin A. H. Berrevoets, Leo A. B. Joosten, Mihai G. Netea, Cheng-Jian Xu, André J. A. M. van der Ven, Yang Li

PMC · DOI: 10.1038/s41467-026-70889-z · Nature Communications · 2026-03-25

## TL;DR

This study explores how CMV infection affects the immune system in people with HIV, identifying FCRL6 as a potential biomarker for immune activation.

## Contribution

The study identifies FCRL6 as a novel biomarker for immune activation in CMV-seropositive people living with HIV.

## Key findings

- CMV seropositivity increases pro-inflammatory cytokine production in immune cells of PLHIV.
- FCRL6 expression is elevated in CMV-seropositive PLHIV, linked to demethylation and increased gene and protein levels.
- Mendelian randomization confirms a causal relationship between elevated FCRL6 and CMV seropositivity.

## Abstract

CMV seropositivity contributes to medical complications in people living with HIV (PLHIV). This study provides a comprehensive evaluation of how CMV seropositivity shapes the immune system of 1,887 PLHIV, by utilizing multi-omics and deep immune phenotyping datasets. The study measured the immune cell profiles from whole blood, and the cytokine production of PBMCs exposed to various ex-vivo stimuli. We observed an increase in pro-inflammatory cytokine production of circulating immune cells and differences in phenotype of innate-like lymphocyte populations associated with CMV seropositivity. This study also measured 5-omics layers, including genomics, DNA methylation, transcriptomics, and plasma protein and metabolites. The DNA methylome and transcriptome demonstrated prominent CMV-induced signatures related to immune functions in PLHIV. Particularly, high FCRL6 expression is a promising biomarker for immune activation, underlined by the demethylation of FCRL6 and up-regulation of gene expression and plasma protein concentrations in CMV-seropositive PLHIV. Host genetics-driven elevation in both gene and protein expression of FCRL6 was also associated with latent CMV infection. A significant CMV-seroprevalence locus was associated with cytokine production capacity and protein abundance. Mendelian randomization analyses demonstrated a causal relationship between elevated FCRL6 expression and CMV seropositivity.

Cytomegalovirus (CMV) seropositivity exacerbates immune complications in people living with HIV (PLHIV). Here, the authors utilize multi-omics and immune phenotyping data and show that CMV seropositivity induces pro-inflammatory cytokines and further identify FCRL6 as a potential biomarker for immune activation.

## Linked entities

- **Genes:** FCRL6 (Fc receptor like 6) [NCBI Gene 343413]

## Full-text entities

- **Genes:** PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, HLA-F (major histocompatibility complex, class I, F) [NCBI Gene 3134] {aka CDA12, HLA-5.4, HLA-CDA12, HLAF}, KLRD1 (killer cell lectin like receptor D1) [NCBI Gene 3824] {aka CD94}, HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) [NCBI Gene 3113] {aka DP(W3), DP(W4), DPA1, HLA-DP1A, HLA-DPA, HLADP}, BMPR2 (bone morphogenetic protein receptor type 2) [NCBI Gene 659] {aka BMPR-II, BMPR3, BMR2, BRK-3, POVD1, PPH1}, KLRC2 (killer cell lectin like receptor C2) [NCBI Gene 3822] {aka CD159c, NKG2-C, NKG2C}, GNLY (granulysin) [NCBI Gene 10578] {aka D2S69E, LAG-2, LAG2, NKG5, TLA519}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) [NCBI Gene 5167] {aka ARHR2, COLED, M6S1, NPP1, NPPS, PC-1}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, GZMH (granzyme H) [NCBI Gene 2999] {aka CCP-X, CGL-2, CSP-C, CTLA1, CTSGL2}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, KIR2DS4 (killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 4 (gene/pseudogene)) [NCBI Gene 3809] {aka CD158I, KIR-2DS4, KIR1D, KIR412, KKA3, NKAT-8}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, ADGRG1 (adhesion G protein-coupled receptor G1) [NCBI Gene 9289] {aka BFPP, BPPR, CDCBM14B, CDCBM15A, GPR56, TM7LN4}, ITGAL (integrin subunit alpha L) [NCBI Gene 3683] {aka CD11A, EV6, HNA-5, LFA-1, LFA1A}, LMOD1 (leiomodin 1) [NCBI Gene 25802] {aka 1D, 64kD, D1, MMIHS3, SM-LMOD, SMLMOD}, HLA-B (major histocompatibility complex, class I, B) [NCBI Gene 3106] {aka AS, B-4901, HLAB}, IDO1 (indoleamine 2,3-dioxygenase 1) [NCBI Gene 3620] {aka IDO, IDO-1, INDO}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, CD14 (CD14 molecule) [NCBI Gene 929], HLA-DRB1 (major histocompatibility complex, class II, DR beta 1) [NCBI Gene 3123] {aka DRB1, HLA-DR1B, HLA-DRB, SS1}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, PPH2 [NCBI Gene 89873], ATF3 (activating transcription factor 3) [NCBI Gene 467], HLA-DQB1 (major histocompatibility complex, class II, DQ beta 1) [NCBI Gene 3119] {aka CELIAC1, HLA-DQB, IDDM1}, IL22 (interleukin 22) [NCBI Gene 50616] {aka IL-21, IL-22, IL-D110, IL-TIF, ILTIF, TIFIL-23}, PPP4C (protein phosphatase 4 catalytic subunit) [NCBI Gene 5531] {aka PP-X, PP4, PP4C, PPH3, PPP4, PPX}, GBP1 (guanylate binding protein 1) [NCBI Gene 2633] {aka hGBP1}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}, FOSL1 (FOS like 1, AP-1 transcription factor subunit) [NCBI Gene 8061] {aka FRA, FRA1, fra-1}, KIR2DL3 (killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3) [NCBI Gene 3804] {aka CD158B2, CD158b, GL183, KIR-023GB, KIR-K7b, KIR-K7c}, CHRNB4 (cholinergic receptor nicotinic beta 4 subunit) [NCBI Gene 1143], DNMT3A (DNA methyltransferase 3 alpha) [NCBI Gene 1788] {aka DNMT3A2, HESJAS, M.HsaIIIA, TBRS}, HLA-E (major histocompatibility complex, class I, E) [NCBI Gene 3133] {aka HLA-6.2, QA1}, HLA-DPB1 (major histocompatibility complex, class II, DP beta 1) [NCBI Gene 3115] {aka DPB1, HLA-DP, HLA-DP1B, HLA-DPB}, SCRIB (scribble planar cell polarity protein) [NCBI Gene 23513] {aka CRIB1, SCRB1, SCRIB1, Vartul, oSCRIB}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, BATF (basic leucine zipper ATF-like transcription factor) [NCBI Gene 10538] {aka B-ATF, BATF1, SFA-2, SFA2}, FCRL6 (Fc receptor like 6) [NCBI Gene 343413] {aka FcRH6}, HLA-DQA1 (major histocompatibility complex, class II, DQ alpha 1) [NCBI Gene 3117] {aka CELIAC1, DQ-A1, DQA1, HLA-DQA, HLA-DQA1*}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, HLA-F-AS1 (HLA-F antisense RNA 1) [NCBI Gene 285830], APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, KCNK3 (potassium two pore domain channel subfamily K member 3) [NCBI Gene 3777] {aka DDSA, K2p3.1, OAT1, PPH4, TASK, TASK-1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}
- **Diseases:** lung inflammation (MESH:D011014), CMV-related complications (MESH:D048909), encephalitis (MESH:D004660), hepatitis B or C (MESH:D006509), -infection (MESH:D007239), HIV (MESH:D015658), Schizophrenia (MESH:D012559), retinitis (MESH:D012173), CMV (MESH:D003586), heart and lung inflammatory diseases (MESH:D008171), AIDS (MESH:D000163), MOFA (MESH:D000081042), COPD (MESH:D029424), congenital (MESH:D008209), PLHIV (MESH:C000719191), cytotoxicity (MESH:D064420), cardiovascular comorbidity (MESH:D002318), immune dysfunction (MESH:D007154), DMSs (MESH:D009371), seropositive (MESH:D006679), myocardial infarction (MESH:D009203), viral infections (MESH:D014777), nicotine dependence (MESH:D014029), inflammation (MESH:D007249), COVID-19 (MESH:D000086382), CMV reactivation (MESH:D000085343), colitis (MESH:D003092), immune dysregulation (OMIM:614878), hypertension (MESH:D006973)
- **Chemicals:** polyvinyl alcohol (MESH:D011142), Brilliant (-), EDTA (MESH:D004492), imiquimod (MESH:D000077271), PBS (MESH:D007854), TE (MESH:D013691), poly I:C (MESH:D011070), CO2 (MESH:D002245), LPS (MESH:D008070)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Staphylococcus aureus (species) [taxon 1280], Mycobacterium tuberculosis (species) [taxon 1773], Candida albicans (species) [taxon 5476], Homo sapiens (human, species) [taxon 9606], Streptococcus pneumoniae (species) [taxon 1313], Cytomegalovirus (genus) [taxon 10358], Zika virus (no rank) [taxon 64320], Escherichia coli (E. coli, species) [taxon 562]
- **Mutations:** rs11629784, rs7180928, rs1959651, rs140233210, rs2021368

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13022287/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13022287/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC13022287/full.md

---
Source: https://tomesphere.com/paper/PMC13022287